These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 17099918)
21. DNA-based aptamer fails as a simultaneous cancer targeting agent and drug delivery vehicle for a phenanthroline-based platinum(II) complex. McGinely NL; Plumb JA; Wheate NJ J Inorg Biochem; 2013 Nov; 128():124-30. PubMed ID: 23954482 [TBL] [Abstract][Full Text] [Related]
22. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell). Meyer-Losic F; Quinonero J; Dubois V; Alluis B; Dechambre M; Michel M; Cailler F; Fernandez AM; Trouet A; Kearsey J J Med Chem; 2006 Nov; 49(23):6908-16. PubMed ID: 17154520 [TBL] [Abstract][Full Text] [Related]
23. A controllable aptamer-based self-assembled DNA dendrimer for high affinity targeting, bioimaging and drug delivery. Zhang H; Ma Y; Xie Y; An Y; Huang Y; Zhu Z; Yang CJ Sci Rep; 2015 May; 5():10099. PubMed ID: 25959874 [TBL] [Abstract][Full Text] [Related]
24. Using aptamers to identify and enter cells. Chu T; Ebright J; Ellington AD Curr Opin Mol Ther; 2007 Apr; 9(2):137-44. PubMed ID: 17458167 [TBL] [Abstract][Full Text] [Related]
25. Selective recognition of co-assembled thrombin aptamer and docetaxel on mesoporous silica nanoparticles against tumor cell proliferation. Gao L; Cui Y; He Q; Yang Y; Fei J; Li J Chemistry; 2011 Nov; 17(47):13170-4. PubMed ID: 22012586 [No Abstract] [Full Text] [Related]
26. Multivalent Aptamer-RNA Conjugates for Simple and Efficient Delivery of Doxorubicin/siRNA into Multidrug-Resistant Cells. Jeong H; Lee SH; Hwang Y; Yoo H; Jung H; Kim SH; Mok H Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27863037 [TBL] [Abstract][Full Text] [Related]
27. Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer. Bayrac AT; Akca OE; Eyidogan FI; Oktem HA J Biosci; 2018 Mar; 43(1):97-104. PubMed ID: 29485118 [TBL] [Abstract][Full Text] [Related]
28. Aptamer-functionalized hydrogel as effective anti-cancer drugs delivery agents. Wang Z; Xia J; Cai F; Zhang F; Yang M; Bi S; Gui R; Li Y; Xia Y Colloids Surf B Biointerfaces; 2015 Oct; 134():40-6. PubMed ID: 26142627 [TBL] [Abstract][Full Text] [Related]
29. Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer. Taghdisi SM; Danesh NM; Sarreshtehdar Emrani A; Tabrizian K; Zandkarimi M; Ramezani M; Abnous K J Drug Target; 2013 Sep; 21(8):739-44. PubMed ID: 23815443 [TBL] [Abstract][Full Text] [Related]
30. Proof of concept for inhibiting metastasis: circulating tumor cell-triggered localized release of anticancer agent via a structure-switching aptamer. Chen N; Yang X; Wang Q; Jian L; Shi H; Qin S; Wang K; Huang J; Liu W Chem Commun (Camb); 2016 May; 52(41):6789-92. PubMed ID: 27121864 [TBL] [Abstract][Full Text] [Related]
31. Cell-specific internalization study of an aptamer from whole cell selection. Xiao Z; Shangguan D; Cao Z; Fang X; Tan W Chemistry; 2008; 14(6):1769-75. PubMed ID: 18092308 [TBL] [Abstract][Full Text] [Related]
32. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Li X; Ding L; Xu Y; Wang Y; Ping Q Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296 [TBL] [Abstract][Full Text] [Related]
33. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery. Gilboa E; Berezhnoy A; Schrand B Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880 [TBL] [Abstract][Full Text] [Related]
34. Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. Fu Z; Xiang J Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266216 [TBL] [Abstract][Full Text] [Related]
35. Novel micelles from graft polyphosphazenes as potential anti-cancer drug delivery systems: drug encapsulation and in vitro evaluation. Zheng C; Qiu L; Yao X; Zhu K Int J Pharm; 2009 May; 373(1-2):133-40. PubMed ID: 19429298 [TBL] [Abstract][Full Text] [Related]
36. Octreotide-Mediated Tumor-Targeted Drug Delivery via a Cleavable Doxorubicin-Peptide Conjugate. Lelle M; Kaloyanova S; Freidel C; Theodoropoulou M; Musheev M; Niehrs C; Stalla G; Peneva K Mol Pharm; 2015 Dec; 12(12):4290-300. PubMed ID: 26524088 [TBL] [Abstract][Full Text] [Related]
37. Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics. Pangburn TO; Petersen MA; Waybrant B; Adil MM; Kokkoli E J Biomech Eng; 2009 Jul; 131(7):074005. PubMed ID: 19655996 [TBL] [Abstract][Full Text] [Related]
38. Aptamer-Mediated Polymeric Vehicles for Enhanced Cell-Targeted Drug Delivery. Tan KX; Danquah MK; Sidhu A; Yon LS; Ongkudon CM Curr Drug Targets; 2018 Feb; 19(3):248-258. PubMed ID: 27321771 [TBL] [Abstract][Full Text] [Related]
39. Smart magnetic nanoparticle-aptamer probe for targeted imaging and treatment of hepatocellular carcinoma. Pilapong C; Sitthichai S; Thongtem S; Thongtem T Int J Pharm; 2014 Oct; 473(1-2):469-74. PubMed ID: 25089503 [TBL] [Abstract][Full Text] [Related]
40. DNA/chitosan nanocomplex as a novel drug carrier for doxorubicin. Cheng X; Zhang F; Zhou G; Gao S; Dong L; Jiang W; Ding Z; Chen J; Zhang J Drug Deliv; 2009 Apr; 16(3):135-44. PubMed ID: 19514973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]